T Lymphocyte Prestimulation Impairs in a Time-Dependent Manner the Capacity of Adipose Mesenchymal Stem Cells to Inhibit Proliferation: Role of Interferon γ, Poly I:C, and Tryptophan Metabolism in Restoring Adipose Mesenchymal Stem Cell Inhibitory Effect

Stem Cells and Development

Volumn 24, Issue 18, 2015, Pages 2158-2170

  Mancheño Corvo, Pablo ^a   Menta, Ramón ^a   Del Río, Borja ^a   Franquesa, Marcella ^b   Ramírez, Cristina ^a   Hoogduijn, Martin J ^b   DeLarosa, Olga ^a   Dalemans, Wilfried ^c   Lombardo, Eleuterio ^a  

^a Engineering and Systems SA Parque Tecnologico de Madrid   (Spain)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TiGenix   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYINOSINIC POLYCYTIDYLIC ACID; STROMAL CELL DERIVED FACTOR 1ALPHA; TRYPTOPHAN;

ADIPOSE DERIVED STEM CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRYPTOPHAN METABOLISM; ADIPOCYTE; ADIPOSE TISSUE; CELL CULTURE; CELL PROLIFERATION; COCULTURE; CYTOLOGY; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM;

ADIPOCYTES; ADIPOSE TISSUE; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; HUMANS; IMMUNOMODULATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; POLY I-C; T-LYMPHOCYTES; TRYPTOPHAN;

EID: 84940906389     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0508     Document Type: Article

References (41)

1. Kosmaczewska A, L Ciszak, J Swierkot, A Szteblich, P Wiland and I Frydecka. (2013). Alterations in both the activatory and inhibitory potential of peripheral blood CD4+ T cells in rheumatoid arthritis patients correlate with disease progression. Pathol Oncol Res 20:235-243.
2. Funderburg NT, SR Stubblefield Park, HC Sung, G Hardy, B Clagett, J Ignatz-Hoover, CV Harding, P Fu, JA Katz, MM Lederman and AD Levin. (2013) Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 140:87-97.
3. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
4. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101:3722-3729.
5. Ghannam S, J Pène, G Moquet-Torcy, C Jorgensen and H Yssel. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302-312.
6. Prigione I, F Benvenuto, P Bocca, L Battistini, A Uccelli and V Pistoia. (2009). Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27:693-702.
7. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancard, V Pistoia and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
8. Raffaghello L, G Bianchi, M Bertolotto, F Montecucco, A Busca, F Dallegri, L Ottonello and V Pistoia. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: amodel for neutrophil preservation in the bone marrow niche. Stem Cells 26:151-162.
9. DelaRosa O, B Sanchez-Correa, S Morgado, C Ram?rez, B del R?o, R Menta, E Lombardo, R Tarazona and JG Casado. (2012). Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev 21:1333-1343.
10. Friedenstein AJ, JF Gorskaja and NN Kulagina. (1976). Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 4:267-274.
11. Zuk PA, M Zhu, P Ashjian, DA De Ugarte, JI Huang, H Mizuno, ZC Alfonso, JK Fraser, P Benhaim and MH Hedrick. (2002). Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:4279-4295.
12. Liotta F, R Angeli, L Cosmi, L Fil?, C Manuelli, F Frosali, B Mazzinghi, L Maggi, A Pasini, et al. (2008). Toll-like receptors 3 and 4 are expressed by human bone marrowderived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26:279-289.
13. Akiyama K, C Chen, D Wang, X Xu, C Qu, T Yamaza, T Cai, WChen, L Sun and S Shi. (2012). Mesenchymal-stemcell-induced immunoregulation involves FAS-ligand-/FASmediated T cell apoptosis. Cell Stem Cell 10:544-555.
14. Doorn J, G Moll, K Le Blanc, C van Blitterswijk and J de Boer. (2012). Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev 18:101-115.
15. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
16. Prasanna SJ, D Gopalakrishnan, SR Shankar and AB Vasandan. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5:e9016.
17. Meisel R, A Zibert, M Laryea, U Göbel,WDäubener and D Dillo. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 103:4619-4621.
18. Ren G, J Su, L Zhang, X Zhao, W Ling, A L'huillie, J Zhang, Y Lu, AI Roberts, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27:1954-1962.
19. Su J, X Chen, Y Huang, W Li, J Li, K Cao, G Cao, L Zhang, F Li, et al. (2014). Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ 21:388-396.
20. DelaRosa O, E Lombardo, A Beraza, P Manchenõ-Corvo, C Ramirez, R Menta, L Rico, E Camarillo, L Garc?a, et al. (2009). Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 15:2795-2806.
21. Menta R, P Manchenõ-Corvo, B Del R?o, C Ram?rez, O DelaRosa, W Dalemans and E Lombardo. (2014). Tryptophan concentration is the main mediator of the capacity of adipose mesenchymal stromal cells to inhibit T-lymphocyte proliferation in vitro. Cytotherapy pii: S1465-S3249(14)00699-9.
22. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, DJ Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
23. Delarosa O, W Dalemans and E Lombardo. (2012). Tolllike receptors as modulators of mesenchymal stem cells. Front Immunol 3:182.
24. Yang SH, MJ Park, IH Yoon, SY Kim, SH Hong, JY Shin, HY Nam, YH Kim, B Kim and CG Park. (2009). Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 41:315-324.
25. Valencic E, E Piscianz, M Andolina, A Ventura and A Tommasini. (2010). The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. Cytotherapy 12: 154-160.
26. Mempel TR, SE Henrickson and UH Von Andrian. (2004). T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154-159.
27. Quah BJ, HS Warren and CR Parish. (2007). Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2:2049-2056.
28. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, B Smith and A Bartholomew. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
29. Duijvestein M, ME Wildenberg, MM Welling, S Hennink, I Molendijk, VL van Zuylen, T Bosse, AC Vos, ES de Jonge-Muller, et al. (2011). Pretreatment with interferon-g enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 29:1549-1558.
30. Ryan JM, F Barry, JM Murphy and BP Mahon. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353-363.
31. Chinnadurai R, IB Copland, SR Patel and J Galipeau. (2014). IDO-independent suppression of T cell effector function by IFN-g-licensed human mesenchymal stromal cells. J Immunol 192:1491-1501.
32. Waterman RS, SL Tomchuck, SL Henkle and AM Betancourt. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 5: e10088.
33. Pevsner-Fischer M, V Morad, M Cohen-Sfady, L Rousso-Noori, A Zanin-Zhorov, S Cohen, IR Cohen and D Zipori. (2007). Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109:1422-1432.
34. Lombardo E, O DelaRosa, P Manchenõ-Corvo, R Menta, C Ram?rez and D Büscher. (2009). Toll-like receptormediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 15:1579-1589.
35. Raicevic G, M Najar, B Stamatopoulos, C De Bruyn, N Meuleman, D Bron, M Toungouz and L Lagneaux. (2011). The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol 270:207-216.
36. Opitz, CA, UM Litzenburger, C Lutz, TV Lanz, I Tritschler, A Köppel, E Tolosa, M Hoberg, J Anderl, et al. (2009). Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrowderived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27:909-919.
37. Raicevic G, R Rouas, M Najar, P Stordeur, HI Boufker, D Bron, P Martiat, M Goldman, MT Nevessignsky and L Lagneaux. (2010). Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol 71:235-244.
38. Mastri M, Z Shah, T McLaughlin, CJ Greene, L Baum, G Suzuki and T Lee. (2012). Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol 303:C1021-C1033.
39. Waterman RS, J Morgenweck, BD Nossaman, AE Scandurro, SA Scandurro and AM Betancourt. (2012). Antiinflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells Transl Med 1:557-565.
40. Zhao X, D Liu, W Gong, G Zhao, L Liu, L Yang and Y Hou. (2014). The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells 32:521-533.
41. Han X, Q Yang, L Lin, C Xu, C Zheng, X Chen, Y Han, M Li, W Cao, et al. (2014). Interleukin-17 enhances immunosuppression by mesenchymal stem cells. Cell Death Differ 21:1758-1768.